SCHEMBL648206

SCHEMBL648206

[c]1ccccc1C1=CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.40
PTGS2 P35354 1/20 0.36
ELANE P08246 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ACMSD Q8TDX5 1/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
JAK3 P52333 1/20 0.31
FFAR2 O15552 3/20 0.30
CASP3 P42574 1/20 0.30
SENP8 Q96LD8 1/20 0.30
SENP7 Q9BQF6 1/20 0.30
SENP6 Q9GZR1 1/20 0.30
PSMB5 P28074 1/20 0.30
CYP1A2 P05177 1/20 0.30
GRM5 P41594 1/20 0.30
TYMP P19971 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676974 0.98 TDP1 (0.39) TDP1PTGS2ELANEMEN1KMT2A
SCHEMBL10793637 0.98 TDP1 (0.39) TDP1PTGS2ELANEMEN1KMT2A
SCHEMBL2658418 0.94 TDP1 (0.34) TDP1PTGS2ACMSD
SCHEMBL2657767 0.84
SCHEMBL17959502 0.70 ACMSD (0.40) TDP1PTGS2ELANEMEN1KMT2A
SCHEMBL9318946 0.70 TDP1 (0.38) TDP1PTGS2ELANEACMSDJAK2
SCHEMBL28772157 0.70 PIK3CD (0.34)
SCHEMBL191429 0.70 ACMSD (0.49) TDP1PTGS2ELANEMEN1KMT2A
SCHEMBL8380044 0.70 ACMSD (0.49) TDP1PTGS2ELANEMEN1KMT2A
SCHEMBL11815728 0.70 PTGS2 (0.59) TDP1PTGS2ELANEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10744349-B2 Nail polish formulation FLINT CHRISTINA (US) 2020-08-18 US claimed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 EP claimed
US-20160220474-A1 Nail Polish Formulation FLINT CHRISTINA (US) 2016-08-04 US claimed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 US claimed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
CN-101610995-A Novel glucagon receptor antagonists METABASIS THERAPEUTICS INC (US) 2009-12-23 CN claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
US-4677184-A Polycarbonate containing cycloalkenylphenyl terminal groups GENERAL ELECTRIC COMPANY (US) 1987-06-30 US claimed
US-10858298-B2 Preparation of diphenyl compounds EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2020-12-08 US disclosed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
US-10744349-B2 Nail polish formulation FLINT CHRISTINA (US) 2020-08-18 US disclosed
US-20190315665-A1 PREPARATION OF DIPHENYL COMPOUNDS EXXONMOBIL RES & ENG CO (US) 2019-10-17 US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
WO-2003024926-A2 METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS REDDY US THERAPEUTICS, INC. (US) 2003-03-27 WO disclosed
US-5510318-A Herbicidal oxazine ethers E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-04-23 US disclosed
US-4282171-A Phosphorus and sulfur containing amides and thioamides THE LUBRIZOL CORPORATION (US) 1981-08-04 US disclosed
US-4208357-A Process for preparing phosphorus and sulfur containing amides and thioamides THE LUBRIZOL CORPORATION (US) 1980-06-17 US disclosed
US-4032461-A PHOSPHORUS AND SULFUR CONTAINING AMIDES AND THIOAMIDES AS LUBRICATING OIL ADDITIVES AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME THE LUBRIZOL CORPORATION (US) 1977-06-28 US disclosed
US-4031023-A Lubricating compositions and methods utilizing hydroxy thioethers THE LUBRIZOL CORPORATION (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 TDP1 4549/4885PTGS2 2305/4885ELANE 3443/4885
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 TDP1 4552/4885PTGS2 2257/4885ELANE 3453/4885
US-20190315665-A1 PREPARATION OF DIPHENYL COMPOUNDS DDT, PCBP1, BMI1 TDP1 1299/4885PTGS2 1364/4885ELANE 4314/4885
US-10858298-B2 Preparation of diphenyl compounds DDT, PCBP1, BMI1 TDP1 1299/4885PTGS2 1364/4885ELANE 4314/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 TDP1 4534/4885PTGS2 2521/4885ELANE 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.